Goodbody Health Inc. - Launch of the Health “MOT” diagnostic test
RNS Number : 8139M
Goodbody Health Inc.
26 May 2022
 

26 May 2022

Goodbody Health Inc.
("Goodbody Health", or the "Company")

Goodbody Health announces the launch of its Health "MOT" diagnostic test


Goodbody Health (AQSE: GDBY) is pleased to announce that it has launched its core UK Health "MOT" test which offers a comprehensive summary of a person's health.  Keenly priced at £99, this new test includes innovative in-clinic diabetes and cholesterol tests, with results finalised in minutes. These tests determine a person's risk for developing cardiac health problems or diabetes over the next 10 years.  Consistent with our value of 'Know More - Live Better", knowing more about one's current wellness empowers the individual to take better control of their health.

 

Goodbody products and services are focussed on prevention and will help alleviate the pressures on the NHS in line with the NHS long term plan.  We are launching to coincide with Type 2 Diabetes prevention week, highlighting 1 in 15 people in the UK has diabetes according to Diabetes UK https://www.diabetes.org.uk/diabetes-the-basics and 1 million people who have type 2 diabetes that have not yet been diagnosed.

This health check, alongside our other diagnostic tests, will start as a trial in a number of chosen pharmacies and our own stores based in Bath and Bristol before rapidly being rolled out nationally. It will be provided within Goodbody's nationwide distribution network of community pharmacies and supported with marketing materials and activities to drive traffic and increase footfall into pharmacies.  The UK population is 67 million and an estimated 95% will visit a pharmacy at least once a year meaning a potential 63.7 million customers.  https://www.rsph.org.uk/resourceLibrary/reducing-premature-mortality-the-role-of-community-pharmacies-.html

 

Geremy Thomas, Executive Chairman, said: "We are very excited about the launch of the MOT product. The recent pandemic has made us all realise that our health is our most important asset, there has never been a better time to take control of your current health. With a number of clinics already on board and the testing available using new, innovative technology, our developing network will soon be able to offer the MOT as an additional product within their pharmacy".

 

For further information:

Marc Howells

Chief Executive Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

enquiries@goodbodyhealth.com

 www.goodbodyhealth.com

Anne Tew

Chief Financial Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

enquiries@goodbodyhealth.com

 www.goodbodyhealth.com

 


 

AQSE Corporate Adviser

Arden Partners plc

Antonio Bossi / George Morgan

+ 44 (0) 20 7614 5900 

 

 

 

 

 

                                                                                                                                                                             

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABKPBDQBKDFPB ]]>